Determination of Viability and Cell Count of T CellsAZoMIn adoptive CAR-T cell therapy, peripheral blood mononuclear cells (PBMC) are taken from the patient and then engineered CAR-T cells are formed by enrichment of the T cell subset of …and mo… Continue reading
AZoMGuide to Determining Viability and Concentration of Stem Cells Grown on MicrocarriersAZoMStem cell research and the significant potentials in stem cell therapy show a great deal of promise in 21st century medical treatments. Since stem cells typica… Continue reading
Healio |
VIDEO: Pembrolizumab may improve response to CAR T-cell therapy in children with ALL
Healio CHICAGO — The combination of pembrolizumab and CAR T-cell therapy appeared safe and effective in a subset of patients with acute lymphoblastic leukemia who did not respond to CAR T-cell therapy or who relapsed due to poor CAR T-cell expansion and … |
|
Nanoparticle–allergen complexes for allergen immunotherapy
Dove Medical Press Abstract: Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new … |
CBS Pittsburgh / KDKA |
New Cancer Treatment Uses Patient’s Immune System To Fight Disease
CBS Pittsburgh / KDKA Those T-cells then go to a specific place where they are manufactured; reprogrammed to actually be able to attack cancer cells,” Dr. Grupp said. These suped-up cells, now called CAR–T cells are then put back in the body where they multiply and get to work. |
|
Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel’s …
GlobeNewswire (press release) Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that the results from the first clinical study of ilixadencel in patients with … |